Physician profile
Salwat Malik
NPI 1548421399
$791.84
in general payments reported to CMS, 2019-2025
13 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2021: $53.57 · 2022: $225 · 2023: $117 · 2024: $67.05 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $333.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $130.40 | 2022-2023 | |
| Novo Nordisk INC | $125.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $80.00 | 2019 | |
| Alnylam Pharmaceuticals INC. | $66.32 | 2025 | Givlaari |
| Astellas Pharma US INC | $64.81 | 2023-2024 | Veozah |
| Lilly USA, LLC | $59.40 | 2021-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $41.27 | 2021-2023 | Benlysta |
| Merck Sharp & Dohme LLC | $36.34 | 2023-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Abbvie INC. | $25.55 | 2025 | |
| Pfizer INC. | $22.47 | 2025 | |
| Davol INC. | $21.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.71 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salwat Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.